Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  7,8-Dihydroxyflavone (7,8-DHF)
Research reference — not for sale

7,8-Dihydroxyflavone (7,8-DHF)

F
lead outcome
Human evidence for any indication
grades vary by outcome ↓
Small molecule (non-peptide)
also called — 7,8-dihydroxyflavone · 78-DHF · tropoflavin · "BDNF mimetic" · "small-molecule TrkB agonist" · INCI: none
flavonoidantioxidantPDXP inhibitionneuroprotection (preclinical)

Status: reference entry — not for sale. No dosing, reconstitution, or administration is published (intentional). Neutral scientific reference only. 7,8-DHF has never been studied in humans; nothing is known about human dose, exposure or safety.

In brief

7,8-Dihydroxyflavone (7,8-DHF, tropoflavin) is a flavone marketed as a "BDNF mimetic" or small-molecule TrkB agonist — the idea being that it does orally what BDNF cannot, since BDNF itself has a short half-life and poor brain penetration. It became the most widely used TrkB agonist in the biomedical literature, with a large rodent record spanning stroke, traumatic brain injury, Alzheimer's, Parkinson's, Huntington's and depression models. Two things should temper that. First, the defining mechanism is contested: multiple independent groups — Todd et al. 2014, Boltaev et al. in Science Signaling 2017, Pankiewicz et al. 2021, and later screening work — could not reproduce direct TrkB activation, and a structural explanation has been proposed for why small molecules may be unable to dimerise the receptor at all. Some of the observed effects appear to be TrkB-independent, attributable to antioxidant activity or to inhibition of PDXP, which 7,8-DHF does demonstrably do. Second, and decisively: there are no human studies of 7,8-DHF for any indication — no efficacy trial, no pharmacokinetics, no safety dataset. A heavily cited rodent compound with a disputed mechanism and zero human data.

Legal standing, by region
European Union
Not approved; not an authorised food supplement ingredient

7,8-DHF holds no marketing authorisation as a medicine and is not an approved novel food or established supplement ingredient in the EU. It is not a permitted cosmetic ingredient. Sold as a research chemical, which does not authorise human use.

United Kingdom
Not approved

No marketing authorisation; research chemical status.

United States · your region
Not FDA-approved; sold as a research chemical / unapproved supplement

Not approved as a drug for any indication. Marketed online in the nootropic space, sometimes as a "supplement", without an established regulatory basis of the kind that a grandfathered dietary ingredient would have. No FDA determination supports its use.

International
Not approved anywhere

Approved in no jurisdiction for any indication.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Human evidence for any indication
This is the central fact of the entry. Everything else here — the extensive animal literature, the mechanistic debate — sits upstream of any human data, of which there is none at all. A compound with hundreds of rodent papers and zero human trials is not a "researched" nootropic in the sense buyers assume.
None. No human clinical trial of 7,8-DHF has been conducted for cognition, neuroprotection, depression, Alzheimer's disease or any other indication. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review states plainly that no human studies have examined whether 7,8-DHF is beneficial. · Nothing demonstrated in humans.
F
Claimed mechanism: direct TrkB agonism ("BDNF mimetic")
This is not a minor technical dispute; it is the reason the compound is sold. Multiple independent groups using quantitative methods report no direct TrkB activation, and a 2024 review in Neural Regeneration Research frames the whole small-molecule TrkB agonist class as needing reappraisal. A plausible structural explanation has been offered: small molecules may simply be unable to bridge and dimerise two TrkB monomers the way a protein ligand can.
Originally reported by Jang, Ye and colleagues (2010 onward) from a cell-based screen: 7,8-DHF was said to bind the TrkB extracellular domain, trigger receptor dimerisation and autophosphorylation, and activate downstream PI3K/Akt and MAPK signalling — reviewed in Liu C, Chan CB, Ye K. Transl Neurodegener. 2016;5:2. **Independently contradicted:** Todd et al. (2014) found 7,8-DHF failed to induce TrkB phosphorylation or to mimic BDNF's protection of striatal neurons. Boltaev et al. (Sci Signal. 2017;10:eaal1670), using multiplex quantitative assays for direct TrkB phosphorylation and downstream kinase activation, could not reproduce receptor activation. Pankiewicz et al. (2021) reached the same conclusion, as did a 2026 screening study developing parallel assays for direct interaction, dimerisation, downstream signalling and cytoprotection. · The defining claim — that this molecule directly activates TrkB the way BDNF does — has repeatedly failed independent replication.
D
Alternative mechanisms (antioxidant activity, PDXP inhibition)
Worth stating carefully: this grade means the molecule has real, characterised activities — not that those activities produce benefit in humans. It also reframes the animal literature, since effects attributed to "TrkB agonism" may be TrkB-independent. That makes the mechanistic story cleaner in one sense and much less supportive of the marketing in another.
7,8-DHF is a flavonoid with genuine antioxidant activity, shown to promote neuronal survival in oxidative-stress models **independently of TrkB expression** (Chen et al., 2011). Separately, structural work combining small-molecule screening, protein crystallography and biolayer interferometry identified 7,8-DHF as a **direct and potent inhibitor of PDXP** (pyridoxal phosphatase), binding with low micromolar affinity and raising PLP in mouse hippocampal neurons in a PDXP-dependent manner. · 7,8-DHF demonstrably does things — it is an antioxidant and a validated PDXP inhibitor with crystallographic evidence.
B
Neuroprotection in animal models
Balanced by negative preclinical results that receive less attention: chronic 7,8-DHF over six months did not improve diaphragm neuromuscular transmission or mitigate sarcopenia in old mice (PMC5256161), and CSF infusion was ineffective at promoting remyelination in cuprizone and EAE models of multiple sclerosis. And the whole body of work faces the standard problem: rodent neuroprotection is where translation most often fails, especially when the proposed mechanism is disputed.
A large and directionally consistent rodent literature: protection in models of ischaemic stroke, traumatic brain injury (post-injury administration reducing tissue damage via PI3K/Akt, PMC4240709), Alzheimer's, Parkinson's and Huntington's disease models, plus antidepressant-like and learning-and-memory effects. Orally bioactive with blood-brain barrier penetration in rodents — the practical advantage over BDNF itself, which has poor half-life and BBB penetration. · Consistent neuroprotective and behavioural effects across many rodent models.
B
Pharmacokinetics and formulation
No human pharmacokinetic data. Flavonoids as a class are subject to extensive first-pass metabolism, and what a rodent achieves orally is a poor guide to human exposure. Nothing is known about what dose, if any, produces meaningful brain concentrations in people.
Orally bioactive and BBB-penetrant in rodents, but with **only modest oral bioavailability and a moderate pharmacokinetic profile** — enough of a limitation that a prodrug of 7,8-DHF was specifically developed to improve it (PNAS 2018;115). · Reaches the brain in rodents; exposure is suboptimal enough to have prompted prodrug development.
—
Human safety
There is no human safety dataset of any kind — no phase 1, no dose escalation, no chronic exposure data. Flavonoid structure and "natural" framing are not safety evidence. Material sold online carries the usual separate risks of unverified purity and content.
No human safety studies. · Unknown.
—
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for 7,8-Dihydroxyflavone (7,8-DHF) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Identity

7,8-Dihydroxyflavone (7,8-DHF, also called tropoflavin) is a naturally occurring flavone — a small polyphenolic molecule of the flavonoid class, formula C₁₅H₁₀O₄ — found in trace amounts in some plants. Unlike almost everything else in this register's research section, it is not a peptide or protein but a conventional small molecule, and it is orally absorbed and crosses the blood-brain barrier in rodents.

Its reputation rests entirely on a proposed identity: that it is a "BDNF mimetic" — a small molecule able to activate the TrkB receptor, the receptor through which brain-derived neurotrophic factor exerts its effects on neuronal survival, plasticity, learning and mood. That framing is the compound's whole commercial and scientific appeal, and it is also the part under sustained dispute.

Development & history

  • 2010: Identified by Jang, Ye and colleagues at Emory University through a cell-based screen for small molecules mimicking BDNF. Reported to bind the TrkB extracellular domain, induce dimerisation and autophosphorylation, and activate PI3K/Akt and MAPK signalling.
  • 2010s: Rapid adoption. 7,8-DHF became the most widely used "TrkB agonist" in the biomedical literature, generating a large rodent record — neuroprotection in ischaemic stroke, traumatic brain injury, Alzheimer's, Parkinson's and Huntington's models, plus antidepressant-like and pro-cognitive effects. Its oral bioactivity and BBB penetration were the selling point, since recombinant BDNF had failed clinically for exactly the opposite reasons.
  • 2014: Todd et al. report that 7,8-DHF (and the related LM22A-4) fail to induce TrkB phosphorylation and fail to mimic BDNF's protection of striatal neurons — the first prominent replication failure.
  • 2017: Boltaev et al. publish in Science Signaling a multiplex quantitative assessment of reported small-molecule TrkB agonists, directly measuring TrkB phosphorylation and downstream kinase activation. They cannot reproduce BDNF-like, dose-dependent receptor activation with these compounds, and conclude the class needs re-evaluation.
  • 2018: A prodrug of 7,8-DHF is developed and published (PNAS) specifically because the parent compound has only modest oral bioavailability and a moderate PK profile.
  • 2021: Pankiewicz and colleagues, developing parallel assays for direct binding, dimerisation, downstream signalling and cytoprotection, again find 7,8-DHF inactive at TrkB.
  • 2020s: A structural study identifies 7,8-DHF as a direct PDXP (pyridoxal phosphatase) inhibitor, with crystallography and binding data — offering a concrete alternative explanation for at least some of its effects. A 2024 review in Neural Regeneration Research asks whether small-molecule TrkB agonists are "the right tool" at all, noting that low-molecular-weight compounds may be structurally incapable of bridging two TrkB monomers.
  • Throughout: No human study of 7,8-DHF has been conducted — not for efficacy, not for pharmacokinetics, not for safety.

Mechanism (as proposed, and as disputed)

The proposed mechanism is direct TrkB agonism: binding the receptor's extracellular domain, driving dimerisation and autophosphorylation, and switching on PI3K/Akt and MAPK signalling — the same cascade BDNF uses. If true, this would be genuinely valuable, because BDNF's own therapeutic use is blocked by its short half-life and inability to cross the blood-brain barrier.

The dispute is about whether that actually happens. Independent laboratories using quantitative, direct measures of receptor phosphorylation have repeatedly failed to see it. The structural objection is straightforward: TrkB activation requires bringing two receptor monomers together, and a molecule the size of a flavone may simply be unable to bridge them the way a protein ligand does.

What 7,8-DHF does demonstrably do is two other things. It is a flavonoid antioxidant, and it protects neurons in oxidative-stress models even without TrkB present — a TrkB-independent route to some of the observed neuroprotection. And it is a potent, direct PDXP inhibitor, established with crystallography, raising pyridoxal phosphate in hippocampal neurons through that target rather than through TrkB. Neither of these is a reason to dismiss the compound; both are reasons to doubt the label it is sold under.

Reading the evidence honestly

Three points, in order of importance.

There are no human data. Not weak human data, not preliminary human data — none. No trial has ever tested 7,8-DHF in people for cognition, mood, neuroprotection or anything else, and there is no human pharmacokinetic or safety dataset. The volume of rodent literature makes the compound feel well-studied, which is precisely the confusion worth naming: hundreds of animal papers and zero human studies is a very specific evidence profile, and it is not the one implied by "extensively researched nootropic".

The headline mechanism has failed independent replication, more than once. Todd 2014, Boltaev 2017 in Science Signaling, Pankiewicz 2021 and later screening work all report no direct TrkB activation, and a mainstream review now treats the entire small-molecule TrkB agonist class as requiring reappraisal. When a compound's defining property cannot be reproduced by independent groups using better assays, that belongs in the first paragraph of any description of it — not in a footnote.

The animal literature is real but should be read differently. The rodent neuroprotection results are numerous and often well conducted; they simply may not be TrkB-mediated. Antioxidant activity and PDXP inhibition are documented alternative routes. There are also negative animal results worth knowing — six months of chronic treatment failed to improve diaphragm neuromuscular function or sarcopenia in old mice, and CSF infusion failed to promote remyelination in two multiple sclerosis models — which sit alongside the positive ones and are cited far less often.

The grade reflects a compound that is chemically real, biologically active in identifiable ways, extensively studied in rodents, sold on a mechanism that independent replication does not support, and never once tested in a human being.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID1880
InChIKeyCOCYGNDCWFKTMF-UHFFFAOYSA-N
SMILESC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C=C3)O)O

via PubChem CID 1880 (7,8-dihydroxyflavone / tropoflavin, C15H10O4), CAS 38183-03-8, ChEMBL CHEMBL75267 — verified by exact name match. A genuine small molecule, so the full identifier set resolves cleanly. · high confidence

Sources — 10 cited
01Liu C, Chan CB, Ye K. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Transl Neurodegener. 2016;5:2.
02Boltaev U, Meyer Y, Tolibzoda F, et al. Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists. Sci Signal. 2017;10:eaal1670.
03Todd D, et al. (2014) — independent report that 7,8-DHF and LM22A-4 failed to induce TrkB phosphorylation or to mimic BDNF protection of striatal neurons from mutant huntingtin-induced death.
04Zagrebelsky M, Korte M. Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor? Neural Regen Res. 2024.
05Structural identification of 7,8-DHF as a direct PDXP (pyridoxal phosphatase) inhibitor by small-molecule screening, protein crystallography and biolayer interferometry.
06Chen J, et al. (2011) — TrkB-independent antioxidant neuroprotection by 7,8-DHF.
07Chen C, et al. The prodrug of 7,8-dihydroxyflavone: development and therapeutic efficacy for treating Alzheimer's disease. PNAS. 2018.
08Post-injury treatment with 7,8-dihydroxyflavone protects against experimental traumatic brain injury via PI3K/Akt signaling (PMC4240709).
09Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction (PMC5256161) — negative result.
10Alzheimer's Drug Discovery Foundation, Cognitive Vitality: 7,8- Dihydroxyflavone — research review noting absence of human studies.
Updated 2026-07-22 (the open question is mechanistic — whether any small molecule can activate TrkB as BDNF does; re-check whether a human study of any kind is ever registered)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
SemaxC
Peptide
CerebrolysinC
Peptide
Dihexa (PNB-0408)F
Peptide
Davunetide (NAP)F
Peptide
Explore by goal
Neuro & cognitive →
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen data
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

7,8-DHF — evidence, uses & regulatory status · Vallydia